胸苷激酶1与恶性肿瘤特异生长因子在晚期结直肠癌患者中的表达及临床意义  

Expression and clinical significance of serum thymidine kinase 1 and tumor specific growth factor in patients with advanced colorectal cancer

作　　者：史恩红[1] 张东利[1] 李兰兰[1] 张春东[1] Shi Enhong;Zhang Dongli;Li Lanlan;Zhang Chundong(Department of Oncology,Heilongjiang Provincial Hospital,Harbin 150000,Heilongjiang,China)

机构地区：[1]黑龙江省医院放疗科,黑龙江哈尔滨150036

出　　处：《实用检验医师杂志》2023年第3期274-277,共4页Chinese Journal of Clinical Pathologist

基　　金：黑龙江省卫生健康卫科技计划(20210303100317)。

摘　　要：目的分析血清胸苷激酶1(TK1)及恶性肿瘤特异生长因子(TSGF)在晚期结直肠癌患者的诊断和疗效评估中的作用。方法选择2021年1月—2022年11月黑龙江省医院收治的46例晚期结直肠癌患者作为观察组,另外选择同期32名健康体检者作为对照组。采集所有受检对象的新鲜外周血,收集血清,使用酶联免疫分析法检测血清TK1、TSGF、癌胚抗原(CEA)、糖类抗原199(CA-199)水平并计算阳性率,评估各指标单独与联合检测在结直肠癌诊断中的效能。46例晚期结直肠癌患者经过XELOX方案化疗4个周期后,按疗效分为CR+PR组(20例)、SD组(10例)、PD组(16例)。比较化疗前后两组上述指标水平差异,分析TK1与TSGF检测在评估化疗疗效中的临床价值。结果观察组的TK1、TSGF、CEA、CA-199表达水平及阳性率均明显高于对照组[TK1(pmol/L):3.22±2.37比0.77±0.58,TSGF(kU/L):73.34±17.06比50.97±8.81,CEA(μg/L):37.49±26.60比2.96±1.48,CA-199(kU/L):66.39±51.74比12.76±7.77,TK1阳性率:65.22%比9.38%,TSGF阳性率:39.13%比9.38%,CEA阳性率:84.78%比6.25%,CA-199阳性率:54.35%比3.13%,均P<0.05]。化疗后CR+PR组、SD组和PD组的TK1、TSGF水平依次升高,差异均有统计学意义[TK1(pmol/L):1.25±1.17、2.40±0.75、5.88±3.82,TSGF(kU/L):61.6±9.89、71.60±21.50、74.69±33.83,均P<0.05];化疗后CR+PR组和SD组的TK1、TSGF水平均明显低于化疗前,PD组的TK1、TSGF水平明显高于化疗前[TK1(pmol/L):CR+PR组:1.25±1.17比3.05±2.03,SD组:2.40±0.75比3.41±1.87,PD组:5.88±3.82比3.31±3.08;TSGF(kU/L):CR+PR组:61.60±9.89比73.85±17.50,SD组:71.60±21.50比73.50±15.43,PD组:74.69±33.83比72.63±18.47;均P<0.05]。结论TK1及TSGF水平检测可以作为临床辅助诊断晚期结直肠癌和评估化疗疗效的理想指标。Objective To analyze the role of serum thymidine kinase 1(TK1)and tumor specific growth factor(TSGF)in the diagnosis and efficacy evaluation of patients with advanced colorectal cancer.Methods From January 2021 to November 2022,a total of 46 patients with advanced colorectal cancer were selected as observation group,and 32 healthy examiners at the same period were selected as control group.Fresh peripheral blood samples of research objects were collected,and the serum was obtained.The levels of TK1,TSGF,carcinoembryonic antigen(CEA)and carbohydrate antigen 199(CA-199)in the serum of two groups were detected using enzyme linked immunosorbent assay,and the positive rates were calculated.The efficacy of individual and combined detection of each indicator in the diagnosis of colorectal cancer was evaluated.After 4 cycles of XELOX regimen chemotherapy,46 patients with advanced colorectal cancer were divided into CR+PR group(20 cases),SD group(10 cases)and PD group(16 cases)based on their efficacy.The differences in the levels of above indicators between the two groups before and after chemotherapy were compared,and the clinical value of TK1 and TSGF expression levels in evaluating chemotherapy efficacy was analyzed.Results The expression levels and positive rates of TK1,TSGF,CEA and CA-199 in observation group were significantly higher than those in control group[TK1(pmol/L):3.22±2.37 vs.0.77±0.58,TSGF(kU/L):73.34±17.06 vs.50.97±8.81,CEA(μg/L):37.49±26.60 vs.2.96±1.48,CA-199(kU/L):66.39±51.74 vs.12.76±7.77,positive rate of TK1:65.22%vs.9.38%,positive rate of TSGF:39.13%vs.9.38%,positive rate of CEA:84.78%vs.6.25%,positive rate of CA-199:54.35%vs.3.13%,all P<0.05].After chemotherapy,the levels of TK1 and TSGF in CR+PR group,SD group and PD group increased sequentially,with statistically significant differences[TK1(pmol/L):1.25±1.17,2.40±0.75,5.88±3.82,TSGF(kU/L):61.60±9.89,71.60±21.50,74.69±33.83,all P<0.05].After chemotherapy,the levels of TK1 and TSGF in CR+PR group and SD group were significantly lowe

关 键 词：晚期结直肠癌 化疗 疗效评估 胸苷激酶1 恶性肿瘤特异生长因子 

分 类 号：R735.34[医药卫生—肿瘤]